
GPCR MOLECULAR PHARMACOLOGY AND DRUG TARGETING

**SHIFTING PARADIGMS AND
NEW DIRECTIONS**

Edited by

Annette Gilchrist

Department of Pharmaceutical Sciences

Midwestern University, Downers Grove, Illinois



A JOHN WILEY & SONS, INC., PUBLICATION

GPCR MOLECULAR PHARMACOLOGY AND DRUG TARGETING

GPCR MOLECULAR PHARMACOLOGY AND DRUG TARGETING

**SHIFTING PARADIGMS AND
NEW DIRECTIONS**

Edited by

Annette Gilchrist

Department of Pharmaceutical Sciences

Midwestern University, Downers Grove, Illinois



A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2010 John Wiley & Sons, Inc. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey.

Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

GPCR molecular pharmacology and drug targeting : shifting paradigms and new directions / edited by Annette Gilchrist.

p. ; cm.

Includes index.

ISBN 978-0-470-30778-6 (cloth)

1. G proteins. 2. Drug targeting. I. Gilchrist, Annette.

[DNLM: 1. Receptors, G-Protein-Coupled-physiology. 2. Drug Delivery Systems. 3. Molecular Structure. QV 38 G725 2010]
QP552.G16G627 2010
612'.015756-dc22

2009052133

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

To Josen and Finn, who arrived somewhere in the middle of all of this ...

CONTENTS

Preface	xvii
Contributors	xix
1. The Evolution of Receptors: From On–Off Switches to Microprocessors	1
<i>Terry Kenakin</i>	
1.1. Introduction	1
1.2. The Receptor as an On–Off Switch	1
1.3. Historical Background and Classical Receptor Theory	2
1.4. The Operational Model of Drug Action	7
1.5. Receptor Antagonism	8
1.6. Specific Models of GPCRs (7TM Receptors)	11
1.7. The Receptor as Microprocessor: Ternary Complex Models	13
1.8. Receptors as Basic Drug Recognition Units	17
1.9. Receptor Structure	19
1.10. Future Considerations	19
References	22
2. The Evolving Pharmacology of GPCRs	27
<i>Lauren T. May, Nicholas D. Holliday, and Stephen J. Hill</i>	
2.1. Agonists, Neutral Antagonists, and Inverse Agonists	27
2.1.1. Affinity and Efficacy	27
2.1.2. Pharmacological Models of Agonism, Antagonism, and Inverse Agonism	32
2.2. LDTRS/Protean Agonism	34
2.3. Molecular Mechanisms of GPCR Ligand Binding	35
2.3.1. Rhodopsin-Like Receptor Binding Sites	35
2.3.2. Ligand Recognition in Class C Receptors	38
2.3.3. Molecular Mechanisms of Rhodopsin-Like Receptor Activation	39
2.4. Two GPCR Ligands Binding at Once— Concept of Allostereism	40
2.4.1. Classes of Allosteric Modulators	40
2.4.2. Pharmacological Models of Allosteric Interactions	41
2.4.3. Advantages of Allosteric Ligands	43
	vii

2.5.	GPCR Dimerization	44
2.5.1.	Dimerization Is Essential for Class C Receptor Function	44
2.5.2.	Is Dimerization Required for Class A GPCR Activation?	46
2.5.3.	Influence of Receptor Dimers on Binding Studies	47
2.5.4.	GPCR Heterodimerization	48
2.6.	Future Perspectives	49
	Acknowledgments	50
	References	50
3.	The Emergence of Allosteric Modulators for G Protein-Coupled Receptors	61
	<i>Karen J. Gregory, Celine Valant, John Simms, Patrick M. Sexton, and Arthur Christopoulos</i>	
3.1.	Introduction	61
3.2.	Foundations of Allosteric Receptor Theory	62
3.3.	Models for Understanding the Effects of Allosteric Modulators	63
3.4.	Types of Allosteric Modulators and Their Properties	65
3.5.	Detection and Quantification of Allosteric Interactions	68
3.5.1.	Radioligand Binding Assays	68
3.5.2.	Functional Assays	70
3.6.	Some Examples of GPCR Allosteric Modulators	73
3.6.1.	Small Molecule Allosteric Modulators	73
3.6.2.	Proteins as Allosteric Modulators	78
3.7.	Concluding Remarks	80
	References	81
4.	Receptor-Mediated G Protein Activation: How, How Many, and Where?	88
	<i>Ingrid Gsandtner, Christian W. Gruber, and Michael Freissmuth</i>	
4.1.	The Mechanical Problem—Three Different Solutions	89
4.1.1.	The Lever-Arm Model	91
4.1.2.	The “Gear-Shift” Model	91
4.1.3.	The “C-Terminal Latch” Model	93
4.1.4.	Are the Three Models Mutually Exclusive?	94
4.2.	Receptor Monomers–Dimers–Oligomers: One Size Fits All?	95
4.2.1.	Evidence for GPCR Dimers	96
4.2.2.	GPCR Dimers Are Not Universally Required as Prerequisites for G Protein Activation	96
4.2.3.	Dimers May Allow for Conformational Switches Underlying Receptor Cross-Talk and Other Forms of Allosterism	99

4.3.	Corrals, Fences, Rafts—Are There Privileged Places for GPCR Activation?	100
4.3.1.	The Actin Cytoskeleton Confines GPCRs by Several Mechanisms	100
4.3.2.	Cholesterol-Rich Domains and Lipid Rafts	103
	Acknowledgments	106
	References	106
5.	Molecular Pharmacology of Frizzleds—with Implications for Possible Therapy	113
	<i>Gunnar Schulte</i>	
5.1.	Introduction	113
5.2.	Frizzleds as WNT Receptors	113
5.2.1.	Frizzleds—The Discovery	113
5.2.2.	The Frizzled Family	114
5.2.3.	Frizzled Ligands	116
5.2.4.	WNT-Frizzled Interactions	116
5.2.5.	Intracellular Posttranslational Modifications	117
5.3.	Frizzled Signaling	120
5.3.1.	β -Catenin-Dependent Signaling	122
5.3.2.	β -Catenin-Independent Signaling	122
5.3.3.	Intracellular Scaffolds (DVL and β -arrestin)	123
5.3.4.	Evidence for G Protein Coupling of FZDs	125
5.3.5.	Unconventional Signaling Modes	126
5.4.	Frizzleds—Physiology and Possible Therapy	127
5.4.1.	Frizzleds in Physiology	127
5.4.2.	Therapeutic Potential	128
5.4.3.	Attacking WNT-FZD Interface?	128
5.4.4.	Anti-DVL Drugs	129
5.4.5.	WNTs as Drugs	129
5.4.6.	Future Directions	130
	Acknowledgments	130
	References	130
6.	Secretin Receptor Dimerization: A Possible Functionally Important Paradigm for Family B G Protein-Coupled Receptors	138
	<i>Kaleeckal G. Harikumar, Maoqing Dong, and Laurence J. Miller</i>	
6.1.	Methodological Approaches to GPCR Oligomerization	139
6.2.	Structural Themes for GPCR Oligomerization	141
6.3.	Functional Effects of GPCR Oligomerization	150
6.4.	Secretin Receptor Oligomerization	151
	References	153

7. Past and Future Strategies for GPCR Deorphanization	165
<i>Angélique Levoye, Nathalie Clement, Elodie Tenconi and Ralf Jockers</i>	
7.1. Introduction	165
7.2. Current Strategies to Identify the Ligand and Function of Orphan 7TM Proteins	168
7.2.1. Reverse Pharmacology	168
7.2.2. Orphan Receptor Strategy	168
7.2.3. Use of Sequence Homology, Cross Genome Phylogenetic Analysis, and Chemogenomics to Predict Candidate Ligands	168
7.2.4. Determination of the Expression Pattern and the Phenotype of Knockout Mice of Orphan 7TM Proteins	170
7.3. Functional Assays for Deorphanization	170
7.3.1. Classical Assays of GPCR Deorphanization	173
7.3.2. Recent Assays in GPCR Deorphanization	174
7.4. Future Directions and New Concepts	176
7.5. Controversial Issues	179
Acknowledgments	181
References	181
8. High-Throughput GPCR Screening Technologies and the Emerging Importance of the Cell Phenotype	191
<i>Terry Reisine and Richard M. Eglén</i>	
8.1. Introduction	191
8.2. How Are GPCR Drugs Discovered?	192
8.3. GPCR Dependence on G Proteins	193
8.4. Technologies for GPCR Compound Screening and Drug Discovery	195
8.4.1. Cell-Free Assays	195
8.4.2. Cell-Based Assays	195
8.4.3. Ca ⁺⁺ Transients for GPCR HTS	196
8.4.4. Reporter Assays for GPCR HTS	198
8.4.5. Universal HTS Assays for GPCRs?	198
8.5. Importance of Target Cells in GPCR HTS Assays	199
8.6. Summary	203
References	204
9. Are “Traditional” Biochemical Techniques Out of Fashion in the New Era of GPCR Pharmacology?	209
<i>Maria Teresa Dell’anno and Maria Rosa Mazzoni</i>	
9.1. Overview	209
9.2. Receptor Binding Assays	210

9.3.	Methods for Measurement of cAMP	216
9.3.1.	Assessments of Adenylyl Cyclase Activity: Methods Using Labeled ATP	216
9.3.2.	Methods Using Nonlabeled ATP	218
9.4.	Conclusions	223
	References	223
10.	Fluorescence and Resonance Energy Transfer Shine New Light on GPCR Function	226
	<i>Carsten Hoffmann and Moritz Bünemann</i>	
10.1.	Overview	226
10.2.	Introduction	226
10.3.	Labeling GPCRs with Fluorescent Tags	227
10.3.1.	Tagging GPCRs with Fluorescent Proteins	227
10.3.2.	Labeling of GPCRs with Fluorescent Dyes	228
10.4.	Detection of Fluorescence and Bioluminescence	231
10.5.	Fluorescence-Based Assays to Study Receptor Localization, Trafficking and Receptor Function	232
10.5.1.	How to Monitor Receptor Function by Means of Fluorescence Microscopy	233
10.6.	Resonance Energy Transfer, a Tool to Get New Insights into GPCR Function	234
10.6.1.	BRET	234
10.6.2.	FRET	234
10.6.3.	Comparison of BRET and FRET	235
10.7.	Analysis of Steady-State Protein–Protein Interaction by Means of RET	236
10.8.	Kinetic Analysis of Protein–Protein Interactions by Means of FRET	237
10.8.1.	G Protein Activity Measured by FRET	238
10.8.2.	Receptor–G Protein Interaction Studied by RET	239
10.8.3.	Kinetics of Receptor–G Protein Interactions	240
10.8.4.	Receptor– β -arrestin Interaction Detected by RET	242
10.9.	Detection of Receptor Function by Fluorescence Resonance Energy	243
10.9.1.	Partial Agonism Detected on the Level of the Receptor	245
10.9.2.	Inverse Agonism Detected at the Level of the Receptor	246
	References	247

11. Integration of Label-Free Detection Methods in GPCR Drug Discovery	252
<i>Oliver Naylor, Magdalena Birker-Robaczewska, and John Gatfield</i>	
11.1. Overview	252
11.2. Introduction	253
11.3. Label-Free Technologies—Past and Present	255
11.3.1. Automated Microscopes and Microbalances	256
11.3.2. Microphysiometry	257
11.3.3. Impedance/RWG	259
11.4. Discussion	270
Acknowledgments	272
References	272
12. Screening for Allosteric Modulators of G Protein-Coupled Receptors	276
<i>Christopher Langmead</i>	
12.1. Introduction	276
12.2. The Allosteric Ternary Complex Model, Radioligand Binding, and Affinity	278
12.3. Beyond Affinity—Functional Assays, Efficacy, and Allosteric Agonism	281
12.4. Allosteric Modulator Titration Curves	286
12.5. The Impact of Functional Assay Format on Allosteric Modulator Screening	289
12.6. Taking Advantage of Structural Understanding of Allosteric Binding Sites	293
12.7. Summary and Future Directions	294
References	295
13. Ultra-High-Throughput Screening Assays for GPCRs	300
<i>Priya Kunapuli</i>	
13.1. Introduction	300
13.2. Assay Types for GPCRs in uHTS	303
13.2.1. Radioligand Displacement Assays	303
13.2.2. Functional Assays	305
13.3. Summary	317
Acknowledgments	319
References	319
14. New Techniques to Express and Crystallize G Protein-Coupled Receptors	324
<i>James C. Errey and Fiona H. Marshall</i>	
14.1. Introduction	324
14.2. Key Problems Limiting Production of 3D GPCR Structures	327

14.3.	History of GPCR Structures	329
14.3.1.	Early Studies on Rhodopsin	329
14.3.2.	Higher Resolution Structures of Bovine Rhodopsin Using X-Ray Crystallography	333
14.3.3.	Squid Rhodopsin	336
14.3.4.	Activated Opsin and Binding to G Proteins	337
14.3.5.	Rhodopsin as a Model for Other GPCRs	340
14.4.	The Search for Other GPCR Structures	340
14.4.1.	Expression of Recombinant Receptors	340
14.4.2.	Factors Influencing GPCR Overexpression	349
14.4.3.	Summary	350
14.5.	Protein Purification and Solubilization	351
14.5.1.	Choice of Detergents for Structural Studies	355
14.5.2.	Crystallization Chaperones	356
14.6.	<i>In Cubo</i> Crystallization	358
14.7.	Engineering Receptor Stability	361
14.8.	Structures of the β_2 AR	365
14.9.	The Adenosine A _{2a} Receptor	369
14.10.	Conclusions and Future Developments	371
	Acknowledgments	371
	References	371
15.	Structure and Modeling of GPCRs: Implications for Drug Discovery	385
	<i>Kimberly A. Reynolds, Vsevolod Katritch, and Ruben Abagyan</i>	
15.1.	Introduction	385
15.2.	High-Resolution GPCR Modeling	389
15.2.1.	From Electron Density to a Full Atom Model Suitable for Drug Discovery: Refinement of Existing Crystal Structures	389
15.2.2.	Ligand-Guided Modeling of Binding Pocket Conformation	392
15.2.3.	Coupling LGM and TM Domain Motions to Capture Binding Site Conformational Changes Necessary for Agonist Recognition	397
15.2.4.	VLS with High-Resolution Models: Antagonist/Agonist Selectivity	398
15.3.	Constructing and Evaluating Homology Models of Other Receptor Types	402
15.3.1.	A Note on De Novo Methods	402
15.3.2.	Criteria for Homology Model Template Selection	403
15.3.3.	Structure and Modeling of Loop Regions	409

15.3.4.	GPCR Model Validation and Evaluation	411
15.3.5.	Ligand Subtype Selectivity in GPCR Models	413
15.4.	Modeling GPCR Functional Features—Analysis of Activation and Signaling	415
15.4.1.	Activation-Related Conformational Changes in GPCRs	416
15.4.2.	Macromolecular Complexes of GPCRs	417
15.5.	Beyond Class A: Modeling of Other GPCR Families	418
15.5.1.	Modeling Secretin (Class B) Family GPCRs	418
15.5.2.	Glutamate/Class C	420
15.5.3.	Orphan GPCRs	421
15.6.	Summary and Conclusions	422
	Acknowledgments	422
	References	422
16.	X-Ray Structure Developments for GPCR Drug Targets	434
	<i>Michael Sabio and Sidney W. Topiol</i>	
16.1.	Overview	434
16.2.	Introduction	434
16.3.	Class A GPCRs	438
16.3.1.	Sequence Homology	438
16.3.2.	Stabilization of X-Ray Structures	438
16.3.3.	The Overall Topology of the 7TM Region	440
16.3.4.	The Binding Site	441
16.3.5.	The ECL2	443
16.3.6.	The Toggle Switch	443
16.3.7.	The Ionic Lock	444
16.3.8.	The ICL3 Region and Activation	445
16.3.9.	Computational Chemistry Successes and Limitations	447
16.4.	Class C GPCRs	449
16.4.1.	Global Architecture	449
16.4.2.	The VFT Domain	450
16.4.3.	The C-rich Domain	451
16.4.4.	Computational Studies	452
16.5.	Conclusions	452
	References	453
17.	Pharmacological Chaperones: Potential for the Treatment of Hereditary Diseases Caused by Mutations in G Protein-Coupled Receptors	460
	<i>Kenneth J. Valenzano, Elfrida R. Benjamin, Patricia René, and Michel Bouvier</i>	
17.1.	Overview	460
17.2.	Introduction	461

17.3.	NDI and the V2R	464
17.4.	RP and the Rhodopsin Receptor	470
17.5.	IHH and the Gonadotropin-Releasing Hormone Receptor	476
17.6.	Other Human Diseases Caused by Inactivating Mutations in GPCRs	479
	17.6.1. Class A GPCRs	479
	17.6.2. Class B GPCRs	482
	17.6.3. Class C GPCRs	483
	17.6.4. Family Frizzled/Smoothed GPCRs	484
17.7.	Considerations for the Therapeutic Use of Pharmacological Chaperones	485
	17.7.1. Pharmacogenetics	485
	17.7.2. Dominant-Negative Effects	486
	17.7.3. Function of Rescued GPCRs with Missense Mutations	488
	17.7.4. Biophysical Requirements of Pharmacological Chaperones	488
	17.7.5. Safety	490
17.8.	Concluding Remarks	490
	Acknowledgments	491
	References	491

Index	511
--------------	------------

PREFACE

Although G protein-coupled receptors (GPCRs) have been the subject of study since the early days of pharmacology, our understanding of this large family of receptors continues to evolve. As a result, texts that discuss these receptors must constantly be rewritten and revised as emerging concepts are brought forth. Although many texts focus on GPCRs, none provide an overall look at the molecular pharmacology of this important target class. This book presents an up-to-date review on how scientists are thinking about GPCRs.

Early work includes the lock and key model of Fisher, and “receptive substances” to explain the biological actions of exogenous chemicals on cell “receptors,” and Clark’s occupancy theory that introduced the idea that the effect of an agonist is proportional to the number of occupied receptors. In the 1960s, the concept of intrinsic activity was introduced to explain the observation that not every agonist of a given receptor induced the same maximum effect. Compounds reaching the maximum were referred to as full agonist and other agonists were named partial agonist. This model was later extended to include drug efficacy and the system-independent concept of intrinsic efficacy. The mathematics applied in the models were relatively simple and allowed calculations to be made on affinity and activity. Looking back, it seems remarkable that most of these concepts were developed when little information on the biochemical nature of receptors or the underlying molecular mechanisms involved in signal transduction were available.

I have been working in the field of GPCRs for about 15 years, a time dwarfed by many of the contributing authors, who are well recognized as being experts in the field. In this time period, many of the basic pharmacology concepts for GPCRs have undergone radical changes. Yet, if one looks back, it seems that years before their general acceptance, there was research to support the paradigm shifts. For example, in 1989 Costa and Herz described antagonists with negative intrinsic activity at wild-type δ -opioid receptors (*PNAS* 1989 86: 7321-7325). Many subsequent studies have confirmed that GPCR proteins can signal in an agonist-independent, constitutive manner, and the concept of inverse agonism is now accepted and included in pharmacology textbooks. But in its early days, the concept of inverse agonism was hotly debated. Thus, the way we think about GPCRs, their basal activity, how they get activated, how they communicate the signal across the cell membrane, how they couple to each other as well as to other receptors and other membrane proteins, how their mutations lead to disease, and the many ways in which

they can be screened for compounds that modulate them are constantly changing.

This textbook will serve as a resource for any scientists (e.g., pharmacologists, chemists, biologists) investigating GPCRs in both academia and industry (pharmaceutical/biotechnology). The book provides a general overview of GPCRs in terms of their biology and pharmacology, as well as recent developments including structure, deorphanization, dimerization, functional selectivity, and accessory proteins. In addition, it presents detailed methods on how to express, manipulate, and measure GPCRs. It is important to recognize that emerging concepts have shaped not only our understanding of GPCR pharmacology but also the drug discovery process itself. Recognition that most of the compounds initially considered to be competitive antagonists were inverse agonists, and studies indicating that the therapeutic outcome of inverse agonists and neutral antagonists can be different, led many companies to initiate drug discovery efforts specifically aimed at identifying inverse agonists. As a result, it is envisaged that this book on the shifting paradigms to GPCR pharmacology will be an essential resource for scientists working to identify compounds that selectively target members of this diverse family.

The book is organized into 17 chapters; the first seven chapters deal with the evolving pharmacology that surrounds this family, including chapters discussing allosteric modulators, receptor dimerization, GPCR deorphanization, G protein activation, and the Frizzled family. The next six chapters deal with methods to screen GPCRs, and include chapters on cell phenotype, “traditional” biochemical techniques, resonance energy transfer, label-free detection, and approaches for ultra-high-throughput screening. The next three chapters present GPCR structures, new ways to express and crystallize the receptors, as well as computational studies such as modeling and rational drug design. The final chapter describes the use of pharmacological chaperones for diseases caused by GPCR mutations.

*Chicago College of Pharmacy
Midwestern University*

ANNETTE GILCHRIST

CONTRIBUTORS

Ruben Abagyan, Bioinformatics and Systems Biology Graduate Program,
University of California, La Jolla, CA

Elfrida R. Benjamin, Amicus Therapeutics, Cranbury, NJ

Magdalena Birker-Robaczewska, Actelion Pharmaceuticals Ltd., Allschwil,
Switzerland

Michel Bouvier, Département de Biochimie, Université de Montréal, Montréal,
Quebec, Canada

Moritz Bünemann, Department of Pharmacology and Toxicology, Philipps-
Universität Marburg, Marburg, Germany

Nathalie Clement, Institut Cochin, Université Paris Descartes, Department of
Cell Biology, Paris, France

Arthur Christopoulos, Monash Institute of Pharmaceutical Sciences and
Department of Pharmacology, Monash University, Victoria, Australia

Maria Teresa Dell'Anno, Department of Psychiatry, Neurobiology,
Pharmacology and Biotechnologies, University of Pisa, Pisa, Italy

Maoqing Dong, Department of Molecular Pharmacology and Experimental
Therapeutics, Mayo Clinic, Scottsdale, AZ

Richard M. Eglen, PerkinElmer Life and Analytical Sciences, Waltham, MA

James C. Errey, Heptares Therapeutics Limited, BioPark, Welwyn Garden
City, Hertfordshire, UK

Michael Freissmuth, Institute of Pharmacology, Center of Biomolecular
Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria

John Gatfield, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland

Karen J. Gregory, Monash Institute of Pharmaceutical Sciences and
Department of Pharmacology, Monash University, Victoria, Australia

Christian W. Gruber, Institute of Pharmacology, Center of Biomolecular
Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria

Ingrid Gsandtner, Institute of Pharmacology, Center of Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria

Kaleeckal G. Harikumar, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, AZ

Stephen J. Hill, The University of Nottingham, Institute of Cell Signalling, School of Biomedical Sciences, Queen's Medical Centre, Nottingham, UK

Carsten Hoffmann, Department of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany

Nicholas D. Holliday, The University of Nottingham, Institute of Cell Signalling, School of Biomedical Sciences, Queen's Medical Centre, Nottingham, UK

Ralf Jockers, Institut Cochin, Université Paris Descartes, Department of Cell Biology, Paris, France

Vsevolod Katritch, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA

Terry Kenakin, Biochemical Reagents and Assay Development, GlaxoSmithKline Research and Development, Research Triangle Park, NC

Priya Kunapuli, In Vitro Sciences, External Discovery and Preclinical Sciences, Merck & Co., West Point, PA

Christopher Langmead, Heptares Therapeutics Limited, BioPark, Welwyn Garden City, UK

Angélique Levoye, Unité de Pathogénie Virale, Department of Virology, Institut Pasteur, Paris, France

Fiona H. Marshall, Heptares Therapeutics Limited, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire, UK

Lauren T. May, The University of Nottingham, Institute of Cell Signalling, School of Biomedical Sciences, Queen's Medical Centre, Nottingham, UK

Maria Rosa Mazzoni, Department of Psychiatry, Neurobiology, Pharmacology and Biotechnologies, University of Pisa, Pisa, Italy

Laurence J. Miller, Department of Molecular Pharmacology and Experimental Therapeutics Mayo Clinic, Scottsdale, AZ

Oliver Naylor, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland

Terry Reisine, Independent Consultant, Los Angeles, CA

Patricia René, Département de Biochimie, Université de Montréal, Montréal, Quebec, Canada

Kimberly A. Reynolds, Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX

Michael Sabio, Lundbeck Research USA, Paramus, NJ

Gunnar Schulte, Section of Receptor Biology and Signaling, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

Patrick M. Sexton, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Victoria, Australia

John Simms, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Victoria, Australia

Elodie Tenconi, Institut Cochin, Université Paris Descartes, Department of Cell Biology, Paris, France

Sidney W. Topiol, Lundbeck Research USA, Paramus, NJ

Celine Valant, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Victoria, Australia

Kenneth J. Valenzano, Amicus Therapeutics, Cranbury, NJ

The Evolution of Receptors: From On–Off Switches to Microprocessors

TERRY KENAKIN

Biochemical Reagents and Assay Development, GlaxoSmithKline Research and Development, Research Triangle Park, NC

... Try to imagine a pharmacology course that made no mention of receptors ...'
—Humphrey Rang, 2006

1.1. INTRODUCTION

The evolution of the receptor concept is traced from the turn of the century where the receptor was an organizational concept to the present day where seven transmembrane (7TM) receptors are considered to be complex control units for cellular function. Drug receptor effect can be quantified without knowledge of molecular mechanism through the operational model of drug action. Alternatively, biochemical knowledge of the receptor as an independent protein unit recognizing both external chemicals and cytosolic protein independently can be used to understand ligand-specific receptor effects and how these might be exploited therapeutically.

1.2. THE RECEPTOR AS AN ON–OFF SWITCH

Historically, the concept of drug receptors began as an abstract idea and continued throughout pharmacology for another 70–80 years as such. Models considering receptors essentially had drugs activate (as a switch) a black box to produce tissue response. It is useful first to consider receptors as pharmacological switches since the theories used to describe drug action in

these systems lay the foundation for the more mechanistically driven models of receptors in use today. These ideas have formed the basis for quantitative receptor theory on which new information about the biochemistry and structure of receptors has been added. These will then be discussed in terms of specific mechanistic models of 7TM receptor function and how these assist in the quantification of drug effect.

1.3. HISTORICAL BACKGROUND AND CLASSICAL RECEPTOR THEORY

What is considered a “given” today, namely that drugs interact with specific binding sites on the cell membrane called receptors, is an extremely important tenet of pharmacology. As stated by Rang [1], it indeed was “Pharmacology’s big idea.” The main reason it is such an important cornerstone of pharmacology is that it introduces order into the apparent chaos of physiology. For example, a simple molecule such as epinephrine mediates a myriad of physiological processes. A large subset of these, namely cardiac chronotropy, inotropy, lusitropy, vascular relaxation, lacrimal, pancreatic, and salivary gland secretion, bronchiole, uterine and urinary bladder muscle relaxation, decreased stomach motility, skeletal muscle tremor, and melatonin synthesis are mediated by a small subset of membrane-bound proteins, specifically β_1 - and β_2 -adrenoceptors. This immediately puts order in the collection of physiological processes in that it gives them a common place to start, namely the interaction of epinephrine with the receptor. This order fits in well with the discipline of medicinal chemistry in that chemists have access to the processes for potential control.

At the turn of the twentieth century, different groups carried out research that caused them to postulate the existence of control points on cells that responded to chemicals, that is, receptors. For example, Paul Ehrlich (1854–1915) carried out studies on agent “606” (salvarsan) for syphilis. His work with dyes and bacteria led him to propose that there are “chemoreceptors” (actually a collection of “amboreceptors,” “triceptors,” and “polyceptors”) on parasites, cancer cells, and microorganisms that could be exploited therapeutically [2]. In Cambridge, John Newport Langley (1852–1926) studied the drug *jaborandi* (contains the alkaloid pilocarpine) and atropine and concluded that receptors were “switches” that received and generated signals and that these switches could be activated or blocked by specific molecules [2]. However, it is A.J. Clark (1885–1941) who is considered the father of modern receptor pharmacology. Clark was the first to suggest, from studies of acetylcholine and atropine, that a unimolecular interaction occurs between a drug and a “substance on the cell.” As he put it [3] ...

... it is impossible to explain the remarkable effects observed except by assuming that drugs unite with receptors of a highly specific pattern....

In fact, it was Clark who described pharmacological phenomena in chemical terms [3, 4], a concept readily accepted today, but quite heretical in Clark's time. The prevailing concepts guiding physiology at the turn of the century were rooted in homeopathic theories (i.e., a fundamental theory centered on the surface tension of the cell membrane) like the Arndt-Schulz Law and Weber-Fechner Law [2]. A generally accepted statement to describe physiologic phenomena was simply that "certain phenomena occur frequently."

One of Clark's most valuable contributions to pharmacology was the application of mathematical rules to the behavior of biological systems. Thus, the dose-response curve became the common currency of pharmacology, and its judicious use in the work of Clark and others built the framework for what had become known as "receptor theory," namely the application of simple thermodynamic rules to pharmacological systems.

An early example of mathematics applied to the study of receptors was provided by A.V. Hill, a student of Langley. He expressed the time course of contraction of frog rectus abdominus to the agonist nicotine (N) through an equilibrium concentration-response curve of the form:

$$Y = \frac{N}{k' + kN} - M \quad (1.1)$$

where Y is contraction height, M is threshold, and k' , k are constants. While this work predated the routine use of binding isotherms to receptor work considerably, Hill lost interest in the approach, and it was left to Irving Langmuir, a chemist at General Electric Company in the United States, to devise an equation for the quantification of molecules binding to a surface, in particular, chemicals to metal filaments for light bulbs. Thus, the Langmuir adsorption isotherm quantifies the fraction of the substance bound to a surface (the pharmacological counterpart being receptor, denoted ρ_A) by a molecule [A] as:

$$\rho_A = \frac{[A]}{[A] + K_A} \quad (1.2)$$

where K_A is the ratio of what Langmuir referred to as the "rate of evaporation" of the substance away from the surface (pharmacologically, the rate of offset of the molecule from the receptor) divided by the "rate of condensation" of the molecule toward the surface (pharmacologically, the rate of onset toward the receptor). In pharmacological terms, the specific terminology for molecules that produced such activation is "agonist." While mechanistically, this equation is based on thermodynamic principles governing agonist binding to receptors, operationally, it also defines the universally observed relationship between agonists and the pharmacological responses they induce to tissues and cells. Thus, any observed receptor-mediated response in any tissue can be summarized by a form of the Langmuir isotherm where the fractional maximum

given by Equation 1.2 is multiplied by the maximal response observed from the preparation ($\text{Response}_A = \rho_A \cdot E_{\max}$):

$$\text{Response}_A = \frac{[A] \cdot E_{\max}}{[A] + EC_{50}} \quad (1.3)$$

where EC_{50} refers to the concentration of agonist A that produces half the maximal response to drug A. It should be noted that Equation 1.3 is written for a system demonstrating a Hill coefficient (in honor of A.V. Hill) of unity. If there is cooperativity in the system (either in the binding of the drug to the receptor [*vide infra*] or in the cellular processes that translate drug binding into cellular response), then Equation 1.3 becomes:

$$\text{Response}_A = \frac{[A]^n \cdot E_{\max}}{[A]^n + EC_{50}^n} \quad (1.4)$$

where n is the Hill coefficient for the dose–response curve. Figure 1.1 shows data from Clark (effect of acetylcholine on frog heart chronotropy) fit to the Langmuir adsorption isotherm (Eq. 1.3). Irrespective of mechanism, it can be seen that the curve shown in Fig. 1.1 concisely summarizes the data. Thus, the




Figure 1.1 (a) Alfred J. Clark (1885–1941), Professor of Pharmacology at University College London and later Chairman of Pharmacology in Edinburgh. Clark applied chemical laws to biological phenomena and is regarded as the father of receptor pharmacology. (b) Clark’s data showing responses of frog heart to acetylcholine. Data points are fit to the Langmuir adsorption isotherm (Eq. 1.3).

16 data points are summarized by a shorthand that states acetylcholine produces a chronotropic effect in the frog heart that begins its effect at 50 nM, is half maximal at 2.8 μ M, and is approximately maximum at 500 μ M.

The adsorption isotherm furnished an extremely useful method of summarizing and handling dose–response data, but what was still required is a way to relate the observed data to the molecular mechanism of the drugs producing the effect. With no independent estimate of the affinity of the agonist he was using, Clark had to assume a one-to-one correspondence between the molecules of agonist he added to his preparation and the quanta of excitation those molecules gave to the tissue; that is, there was no provision for variance in the “power” of the molecules to induce tissue response. Ariens and Van Rossum, leading a germinal receptor group in Nijmegen, began the process of relating the molecular mechanism of drugs to the observed effects of drugs [5–7]. Thus was introduced the concept of “intrinsic activity,” denoted α , as a scaling factor to accommodate the observation that not all agonists produce the maximal response of the preparation. Under these circumstances, Equation 1.4 becomes:

$$\text{Response}_A = \frac{[A]^n \cdot \alpha \cdot E_{\max}}{[A]^n + EC_{50}^n} \quad (1.5)$$

where, for $\alpha = 0.5$, this would depict a drug that produced 50% of the tissue maximal response. Intrinsic activity became the first parameter designed to scale observed drug effect with the molecular “power” of an agonist to induce response. While this improved the correspondence between some observed effects of agonists, it was left to R.P. Stephenson, a pharmacologist working in Edinburgh, to extend this process to another level. Stephenson postulated that there was no reason to assume that tissue response was linked to agonist concentration in a linear manner (as was the requirement of the Clark and Ariens treatments). Instead, he postulated the existence of a theoretical parameter he called “stimulus,” which is the result of the immediate interaction of the drug with the receptor [8]. This stimulus is imparted to the cell which then processes it in various ways, according to its needs, to yield tissue response. This loosely defined a function (referred to as the stimulus–response function) relating tissue excitation and response. Thus, tissue response was given as:

$$\text{Response}_A = f \left[\frac{[A] \cdot e \cdot E_{\max}}{[A] + K_A} \right] \quad (1.6)$$

where e is a term efficacy (used to depict the power of the drug to produce response) and f is the stimulus–response mechanism. The important aspect of Equation 1.6 is that it allows the tissue response to be dissociated from receptor occupancy; experimental data would soon show the importance of that feature of the model.

Stephenson's concept of efficacy was required because of his observation that a series of related alkyltrimethylammonium compounds produced different maximal levels of guinea pig ileal contractions within a similar concentration range [8]. Since the agonist potencies indicated that the compounds had similar affinities for the receptor, Stephenson reasoned that another property of these molecules had to be operative to make them dissimilar in terms of producing muscle contraction; that was the property he termed "efficacy." This concept opened up a completely new way to look at tissue activation through receptors. Specifically, there were no constraints regarding the power of molecules to produce pharmacological response. Technically, powerful agonists could produce maximal tissue response by activating only a portion of the available receptors; the remaining portion would thus be described as being "spare" or not required for the production of maximal response. This offered maximal control to tissue systems since the cellular receptor density (i.e., varying proportions of spare receptors)




Figure 1.2 Response of guinea pig ileum to contraction by histamine and the relationship between histamine receptor occupancy and tissue response. (a) Contractile responses of guinea pig ileum to histamine. Ordinates: percent maximal contraction to histamine (solid lines) or calculated receptor occupancy from Langmuir adsorption isotherm (Eq. 1.2) for dotted line. Abscissae: logarithm of molar concentrations of histamine. Data shown for control ($n = 12$) and after alkylation of a portion of the population of histamine receptors with SY-28 (*N*-ethyl-*N*- β -bromoethyl)-1'-naphylmethylamine) (200 nM exposure for 3 min followed by 3 h wash; $n = 8$). Data from Reference 11. (b) Calculated relationship between histamine receptor occupancy (dotted line in panel A) and control histamine response. This is the experimentally derived stimulus-response relationship between histamine and guinea pig ileum. Note the abscissal axis for panel B does not extend to complete receptor occupancy and that essentially 100% tissue response is obtained with an 18% histamine receptor occupancy.